Cases sequenced from metastatic sites showed a significantly elevated rate of BCL2L1 amplification compared with primary-site tumor samples (16% [17/107] vs. 2% [1/41], p = 0.0248), particularly in cases sequenced from liver metastases (20%; 7/35 cases). This evidence concerns the gene BCL2L1 and neoplasm.